Literature DB >> 19689309

The hypocretins and their role in narcolepsy.

Daniel Kroeger1, Luis de Lecea.   

Abstract

A series of discoveries spanning the last decade have uncovered a new neurotransmitter - hypocretin - and its role in energy metabolism, arousal, and addiction. Also, notably, a lack of hypocretin function has been unequivocally associated with the sleep disorder narcolepsy. Here we review these findings and discuss how they will influence future treatments of narcolepsy and other arousal and hyperarousal disorders. We introduce the concept of the hypocretin peptides and receptors and discuss the neuroanatomy and neurophysiology of the hypocretin system. A gain of function through pharmacolological and optogenetic means is also addressed in the following text, as is the loss of function: specifically narcolepsy in dogs, mice and humans and the challenges currently faced in treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689309     DOI: 10.2174/187152709788921645

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  Reduced hypocretin (orexin) levels in dementia with Lewy bodies.

Authors:  Stephanie Lessig; Kiren Ubhi; Douglas Galasko; Anthony Adame; Emiley Pham; Kelly Remidios; Michael Chang; Lawrence A Hansen; Eliezer Masliah
Journal:  Neuroreport       Date:  2010-08-04       Impact factor: 1.837

2.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

3.  Allergies and Disease Severity in Childhood Narcolepsy: Preliminary Findings.

Authors:  Secil Aydinoz; Yu-Shu Huang; David Gozal; Clara O Inocente; Patricia Franco; Leila Kheirandish-Gozal
Journal:  Sleep       Date:  2015-12-01       Impact factor: 5.849

Review 4.  Shining light on wakefulness and arousal.

Authors:  Luis de Lecea; Matthew E Carter; Antoine Adamantidis
Journal:  Biol Psychiatry       Date:  2012-03-20       Impact factor: 13.382

Review 5.  Sleep disturbances in Alzheimer's and Parkinson's diseases.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2012-05-03       Impact factor: 3.843

Review 6.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.